目的 探討銀杏葉片聯(lián)合美托洛爾治療冠心病心力衰竭患者的臨床效果。方法 選取2013年9月-2016年1月如皋市人民醫(yī)院收治的冠心病心力衰竭患者90例，隨機(jī)分為對照組和治療組，每組各45例。對照組患者在常規(guī)治療基礎(chǔ)上口服酒石酸美托洛爾控釋片，2次/d，起始劑量為6.25 mg/d，1～2周后每天增加6.25 mg，逐步增至25～75 mg/d。治療組在對照組的基礎(chǔ)上口服銀杏葉片，1片/次，3次/d。兩組患者連續(xù)治療3個(gè)月。評價(jià)兩組臨床療效，同時(shí)比較兩組患者心功能、超敏C反應(yīng)蛋白（hs-CRP）和腦鈉肽（BNP）水平改善情況。結(jié)果 治療后，對照組和治療組的總有效率分別為71.11%和86.67%，兩組總有效率比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者左心室舒張末期內(nèi)徑（LVEDD）和左室收縮末內(nèi)徑（LVESD）均明顯降低，同時(shí)左心射血分?jǐn)?shù)（LVEF）顯著升高，同組治療前后差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；與對照組相比，治療后治療組上述心功能指標(biāo)顯著優(yōu)于對照組，差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者血清hs-CRP和BNP水平均顯著下降（P<0.05）；且治療后治療組血清hs-CRP和BNP水平改善更顯著（P<0.05）。結(jié)論 銀杏葉片聯(lián)合美托洛爾治療冠心病心力衰竭患者效果顯著，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the clinical effect of Yinxingye Tablets combined with metoprolol in treatment of coronary heart disease with heart failure. Methods Patients (90 cases) with coronary heart disease with heart failure in the People's Hospital of Rugao from September 2013 to January 2016 were randomly divided into the control and treatment groups, and each group had 45 cases. The patients in the control group were po administered with Metoprolol Tartrate Controlled-release Tablets on the basis of conventional treatment, twice daily, the initial dosage was 6.25 mg/d, and increased by 6.25 mg per day after 1-2 weeks, gradually to 25-75 mg/d. The patients in the treatment group were po administered with Yinxingye Tablets on the basis of the control group, 1 tablet/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, and the improvement of heart function, hs-CRP and BNP levels in two groups was compared. Results After treatment, the clinical efficacy in the control and treatment group was 71.11% and 86.67%, respectively, and there were differences between two groups (P<0.05). After treatment, LVEDD and LVESD in two groups were significantly decreased, at the same time, LVEF was significantly increased, and the difference was statistically significant in the same group (P<0.05). And these heart function indicators in the treatment group were better than those in the control group, with significant difference between two groups (P<0.05). After treatment, hs-CRP and BNP in two groups were significantly decreased (P<0.05). And the hs-CRP and BNP levels in the treatment group were decreased more obviously than those in the control group (P<0.05). Conclusion Yinxingye Tablets combined with metoprolol has a significant clinical effect in treatment of coronary heart disease patients with heart failure, which has a certain clinical application value.